Skip to main content

Table 1 Rheumatoid arthritis study population

From: Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity

Laboratory and clinical data RA patients (n = 59)
Disease duration in days, mean ± SD 16 ± 11
Erosive RA, number (percentage) 54 (92)
Positive rheumatoid factor, >10 IU, ELISA, number (percentage) 52 (88)
Positive anti-CCP antibodies, >10 IU, ELISA, number (percentage) 52 (88)
ESR in mm/hour, mean ± SD; ESR >28, number (percentage) 28 ± 21; 35 (59)
CRP in mg/dL, mean ± SD; CRP >15, number (percentage) 25 ± 41; 23 (39)
DAS-28, mean ± SD 4.36 ± 1.7
   DAS-28 < 2.6, number (percentage) 11 (19)
   2.6 < DAS-28 < 5.1, number (percentage) 21 (35)
   DAS-28 > 5.1, number (percentage) 27 (46)
Methotrexate, number (percentage) 49 (83)
Low dose of prednisone, ≤10 mg/day, number (percentage) 54 (92)
Anti-tumor necrosis factor agents, number (percentage) 11 (17)
Anti-CD20 agents, number (percentage) 12 (20)
  1. anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS-28, 28-joint disease activity score; ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; SD, standard deviation.